BRPI0721259C1 - composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto - Google Patents

composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto

Info

Publication number
BRPI0721259C1
BRPI0721259C1 BRPI0721259A BRPI0721259A BRPI0721259C1 BR PI0721259 C1 BRPI0721259 C1 BR PI0721259C1 BR PI0721259 A BRPI0721259 A BR PI0721259A BR PI0721259 A BRPI0721259 A BR PI0721259A BR PI0721259 C1 BRPI0721259 C1 BR PI0721259C1
Authority
BR
Brazil
Prior art keywords
compost
tyr
pharmaceutical composition
making
dpro
Prior art date
Application number
BRPI0721259A
Other languages
English (en)
Inventor
Romagnoli Barbara
Ludin Christian
Obrecht Daniel
Gombert Frank
Henze Heiko
Wim Vrijbloed Jan
Anthony Robinson John
Moehle Kerstin
Mukherjee Reshmi
J Demarco Steven
Original Assignee
Polyphor Ltd
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ltd, Univ Zuerich filed Critical Polyphor Ltd
Publication of BRPI0721259A2 publication Critical patent/BRPI0721259A2/pt
Publication of BRPI0721259B1 publication Critical patent/BRPI0721259B1/pt
Publication of BRPI0721259B8 publication Critical patent/BRPI0721259B8/pt
Publication of BRPI0721259C1 publication Critical patent/BRPI0721259C1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Non-Reversible Transmitting Devices (AREA)

Abstract

composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto. os peptidomiméticos tipo grampo de cabelo (beta) fixados sobre matriz ciclo(-tyr-his-x-cys-ser-ala-dpro-dab-arg-tyr-cys-tyr-gln-lys- pro-pro), ligação de dissulfeto entre cys4 e gys11, e sais farmaceuticamente aceitáveis destes, com x sendo ala ou tyr, têm propriedades antagonizadoras cxcr4 e podem ser usados para prevenir infecções por hiv em indivíduos saudáveis ou para diminuir e parar a progressão viral em pacientes infectados; ou onde o câncer é mediado ou resultante da atividade receptora de cxcr4; ou onde as doenças imunológicas são mediadas ou resultantes da atividade receptora de cxcr4; ou para tratar a imunossupressão; ou, em particular, para a mobilização das células tronco das células tronco do sistema periférico e/ou célula tronco mesenquimal (msc) e/ou outras células tronco cuja retenção depende do receptor de cxcr4. estes peptidomiméticos tipo grampo de cabelo (beta) podem ser fabricados através de um processo que é fundamentado em um estratégia sintética de fase sólida e de solução, usando métodos que são bem, conhecidos àqueles adequadamente habilitados na química peptídica.
BRPI0721259A 2007-02-28 2007-02-28 composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto BRPI0721259C1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CH2007/000101 WO2008104090A1 (en) 2007-02-28 2007-02-28 Template-fixed peptidomimetics

Publications (4)

Publication Number Publication Date
BRPI0721259A2 BRPI0721259A2 (pt) 2013-01-15
BRPI0721259B1 BRPI0721259B1 (pt) 2020-04-07
BRPI0721259B8 BRPI0721259B8 (pt) 2020-09-15
BRPI0721259C1 true BRPI0721259C1 (pt) 2021-05-25

Family

ID=37891752

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0721259A BRPI0721259C1 (pt) 2007-02-28 2007-02-28 composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto

Country Status (21)

Country Link
US (7) US8399611B2 (pt)
EP (1) EP2132221B1 (pt)
JP (1) JP5140686B2 (pt)
KR (1) KR101479148B1 (pt)
CN (1) CN101641372B (pt)
AT (1) ATE475667T1 (pt)
AU (1) AU2007348171B2 (pt)
BR (1) BRPI0721259C1 (pt)
CA (1) CA2679414C (pt)
DE (1) DE602007008150D1 (pt)
DK (1) DK2132221T3 (pt)
EA (1) EA017583B1 (pt)
ES (1) ES2349879T3 (pt)
HK (1) HK1138011A1 (pt)
IL (1) IL200312A (pt)
MX (1) MX2009008843A (pt)
NO (1) NO342598B1 (pt)
NZ (1) NZ579875A (pt)
PL (1) PL2132221T3 (pt)
PT (1) PT2132221E (pt)
WO (1) WO2008104090A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079597A1 (en) 2006-01-16 2007-07-19 Polyphor Ltd. Template - fixed peptidomimetics with antimicrobial activity
CA2676865C (en) 2007-01-29 2018-09-25 Polyphor Ltd. Template - fixed peptidomimetics
AU2007348171B2 (en) 2007-02-28 2012-09-06 Polyphor Ltd. Template-fixed peptidomimetics
EP2427476B1 (en) * 2009-05-07 2018-08-08 Polyphor Ag Beta-hairpin peptidomimetics having cxcr4 antagonizing activity
WO2011066869A1 (en) * 2009-12-04 2011-06-09 Polyphor Ag Beta-hairpin peptidomimetics
BR112013029482A2 (pt) 2011-05-16 2016-08-09 Genzyme Corp utilização de antagonistas cxr4
BR112013031575B1 (pt) * 2011-06-07 2021-03-16 Polyphor Ag Composto peptídico ciclado de estrutura principal, composição farmacêutica, uso de um composto, e, processo para a manufatura de um composto
ES2576959T3 (es) * 2011-10-07 2016-07-12 Polyphor Ag Peptidomiméticos fijados sobre plantilla como inhibidores del FPR1
JP6047231B2 (ja) * 2012-06-06 2016-12-21 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ β−ヘアピンペプチド模倣薬
EP2882770B1 (en) * 2012-08-08 2017-05-31 Polyphor AG Combinations with a backbone-cyclized peptide
WO2020071520A1 (ja) * 2018-10-05 2020-04-09 株式会社ステムリム 間葉系幹細胞の動員活性を有するペプチド
WO2022106061A1 (en) 2020-11-19 2022-05-27 Polyphor Ag Pharmaceutical combinations comprising a peptide cxcr4 inhibitor and a taxane for treating cancer
WO2022184320A2 (en) 2021-03-03 2022-09-09 Spexis Ag Medical use of cyclic peptides
WO2023285681A1 (en) 2021-07-16 2023-01-19 Spexis Ag Pharmaceutical combinations for treating cancer
WO2023285677A1 (en) 2021-07-16 2023-01-19 Spexis Ag Pharmaceutical combinations for treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2382931C (en) * 1999-08-30 2011-01-25 Polyphor Ag Synthesis of template-fixed .beta.-hairpin loop mimetics
ES2527339T3 (es) * 2001-02-23 2015-01-23 Polyphor Ltd. Peptidomiméticos fijados a patrón con actividad antimicrobiana
CN101157924A (zh) 2001-12-11 2008-04-09 人体基因组科学有限公司 嗜中性白细胞因子α
WO2003057173A2 (en) * 2002-01-07 2003-07-17 Sequoia Pharmaceuticals Broad spectrum inhibitors
CN1688600B (zh) 2002-08-20 2010-04-28 波利弗尔有限公司 具有抗菌活性的模板固定的肽模拟物
US7855179B2 (en) 2002-10-02 2010-12-21 Polyphor Ltd. Template-fixed peptidomimetics with antimicrobial activity
ATE395355T1 (de) 2003-05-02 2008-05-15 Polyphor Ag Matrizenfixierte peptidmimetika als medikamente gegen hiv und krebs
AU2003232253A1 (en) * 2003-05-02 2004-11-23 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
US7681235B2 (en) 2003-05-19 2010-03-16 Radware Ltd. Dynamic network protection
ES2491166T3 (es) 2003-11-15 2014-09-05 Polyphor Ltd. Miméticos de lazo de horquilla beta fijados a patrón y su utilización en exposición en fagos
DK1856140T3 (en) 2005-02-17 2014-03-10 Polyphor Ltd Matrix-fixed beta-hairpin shaped peptidomimetics with protease inhibitory activity
WO2006117011A1 (en) 2005-05-02 2006-11-09 Polyphor Ltd. Dye conjugates of template-fixed peptidomimetics
WO2007079597A1 (en) 2006-01-16 2007-07-19 Polyphor Ltd. Template - fixed peptidomimetics with antimicrobial activity
CA2676865C (en) 2007-01-29 2018-09-25 Polyphor Ltd. Template - fixed peptidomimetics
AU2007348171B2 (en) 2007-02-28 2012-09-06 Polyphor Ltd. Template-fixed peptidomimetics
WO2010015287A2 (en) 2008-08-08 2010-02-11 Polyphor Ag Template-fixed peptidomimetics
WO2010060479A1 (en) 2008-11-26 2010-06-03 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
EP2427476B1 (en) 2009-05-07 2018-08-08 Polyphor Ag Beta-hairpin peptidomimetics having cxcr4 antagonizing activity
US9695191B2 (en) 2009-08-05 2017-07-04 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
WO2011060832A1 (en) 2009-11-20 2011-05-26 Polyphor Ag Template-fixed peptidomimetics with ccr10 antagonistic activity
WO2011066869A1 (en) 2009-12-04 2011-06-09 Polyphor Ag Beta-hairpin peptidomimetics
ES2570458T3 (es) 2010-02-05 2016-05-18 Polyphor Ag Peptidomiméticos fijados sobre una matriz con actividad moduladora de CXCR7
WO2011095218A1 (en) 2010-02-05 2011-08-11 Polyphor Ag Template-fixed pep tidomime tics with cxcr7 modulating activity
US8895499B2 (en) 2010-08-05 2014-11-25 Polyphor Ag β-hairpin peptidomimetics
BR112013031575B1 (pt) 2011-06-07 2021-03-16 Polyphor Ag Composto peptídico ciclado de estrutura principal, composição farmacêutica, uso de um composto, e, processo para a manufatura de um composto
ES2576959T3 (es) 2011-10-07 2016-07-12 Polyphor Ag Peptidomiméticos fijados sobre plantilla como inhibidores del FPR1
SG11201405628YA (en) 2012-03-17 2014-10-30 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
JP6047231B2 (ja) 2012-06-06 2016-12-21 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ β−ヘアピンペプチド模倣薬
EP2882770B1 (en) 2012-08-08 2017-05-31 Polyphor AG Combinations with a backbone-cyclized peptide
RS56350B1 (sr) 2012-08-08 2017-12-29 Polyphor Ag Kombinacije sa peptidom sa ciklizovanim osnovnim lancem
US9938322B2 (en) 2013-03-30 2018-04-10 Polyphor Ag β-hairpin peptidomimetics
AU2014247189C1 (en) 2013-03-30 2019-05-16 Polyphor Ag Beta-hairpin peptidomimetics
WO2015096873A1 (en) 2013-12-27 2015-07-02 Polyphor Ag Beta-hairpin peptidomimetics as selective elastase inhibitors
BR112016015018B1 (pt) 2013-12-27 2022-10-04 Polyphor Ag Composto peptídico ciclizado na cadeia principal, composição farmacêutica, uso de um composto, método para tratar uma infecção ou uma doença ou distúrbio, e, processo para a fabricação de um composto

Also Published As

Publication number Publication date
PT2132221E (pt) 2010-10-26
US20100048463A1 (en) 2010-02-25
US20200399317A1 (en) 2020-12-24
AU2007348171B2 (en) 2012-09-06
ES2349879T3 (es) 2011-01-12
MX2009008843A (es) 2009-08-28
KR20100014596A (ko) 2010-02-10
ATE475667T1 (de) 2010-08-15
US20180127467A1 (en) 2018-05-10
BRPI0721259A2 (pt) 2013-01-15
US8921325B2 (en) 2014-12-30
US20150080317A1 (en) 2015-03-19
US20190100558A1 (en) 2019-04-04
DK2132221T3 (da) 2010-11-22
CN101641372A (zh) 2010-02-03
BRPI0721259B1 (pt) 2020-04-07
KR101479148B1 (ko) 2015-01-05
US20130150299A1 (en) 2013-06-13
HK1138011A1 (en) 2010-08-13
US11421001B2 (en) 2022-08-23
NZ579875A (en) 2012-02-24
IL200312A (en) 2014-11-30
CA2679414A1 (en) 2008-09-04
CA2679414C (en) 2014-10-28
US9879047B2 (en) 2018-01-30
US10787486B2 (en) 2020-09-29
WO2008104090A1 (en) 2008-09-04
JP2010519331A (ja) 2010-06-03
EA017583B1 (ru) 2013-01-30
JP5140686B2 (ja) 2013-02-06
BRPI0721259B8 (pt) 2020-09-15
NO20093064L (no) 2009-09-28
AU2007348171A1 (en) 2008-09-04
IL200312A0 (en) 2010-04-29
CN101641372B (zh) 2012-11-28
US10144765B2 (en) 2018-12-04
DE602007008150D1 (de) 2010-09-09
US20170096453A1 (en) 2017-04-06
EP2132221A1 (en) 2009-12-16
EA200901178A1 (ru) 2010-04-30
NO342598B1 (no) 2018-06-18
EP2132221B1 (en) 2010-07-28
US9556234B2 (en) 2017-01-31
PL2132221T3 (pl) 2011-04-29
US8399611B2 (en) 2013-03-19

Similar Documents

Publication Publication Date Title
BRPI0721259B8 (pt) composto, composição farmacêutica, uso de composto, e, processo para a fabricação de composto
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
CL2003002731A1 (es) Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe
WO2007022257A3 (en) Monocyclic and bicyclic compounds and methods of use
BR122016022033B8 (pt) conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica
CL2011002056A1 (es) Compuestos derivados del acido {7-([1,2,3]triazol-1-il)-6,7,8,9-tetrahidropirido[1,2-a]indol-10-il}-acetico, antagonista del receptor crth2; composicion farmaceutica que lo comprende; utiles ene l tratamiento del asma, alergias, cancer entre otras.
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
MX2009003129A (es) Derivados de oxadiazol con propiedades anti-inflamatorias e inmunosupresoras.
EP3744340A3 (en) Compositions and methods for treating cancer
WO2010068287A8 (en) Small molecule modulators of hepatocyte growth factor (scatter factor) activity
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
PH12019550241A1 (en) Mic-1 compounds and uses thereof
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
BRPI0918517B8 (pt) composto, composição farmacêutica, e, uso de um composto
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
MY146671A (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
MX2021006012A (es) Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso.
WO2008049098A3 (en) ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1
TW200716555A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
CL2008001322A1 (es) Compuestos derivados de triazolil-aminopirimidina, sustituida con heterociclos; composicion farmaceutica; y uso en el tratamiento del cancer.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2570 DE 07/04/2020 QUANTO AO INVENTOR.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/02/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22B Petition not considered [chapter 22.2 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 870210067284, DE 23/07/2021, EM VIRTUDE DO DISPOSTO NO ART. 219 , INCISO II DA LPI